Intranasal Carnosine Compositions for Neurodegenerative Disease Treatment
Summary
The USPTO published patent application US20260108582A1 on April 23, 2026, titled 'Compositions and Methods for Intranasal Delivery of Carnosine for Treatment of Neurodegenerative Diseases and Disorders.' Inventors Spencer Bouhadir and Jacob J. Miguel filed the application on March 4, 2025, under Application No. 19070338. The patent covers compositions and methods for intranasal delivery of carnosine, classified under CPC codes including A61K 38/05, A61K 9/0043, and A61P 25/16.
“The present disclosure provides, inter alia, compositions and methods for intranasal delivery of carnosine.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published a patent application covering compositions and methods for intranasal delivery of carnosine for treatment of neurodegenerative diseases and disorders. The patent application was filed on March 4, 2025, and published on April 23, 2026, with inventors Spencer Bouhadir and Jacob J. Miguel.
Pharmaceutical and biotechnology companies researching neurological therapeutics, drug delivery systems, or carnosine-related formulations should review this publication for potential licensing opportunities or to assess Freedom to Operate considerations in this therapeutic area.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS
Application US20260108582A1 Kind: A1 Apr 23, 2026
Inventors
Spencer Bouhadir, Jacob J. Miguel
Abstract
The present disclosure provides, inter alia, compositions and methods for intranasal delivery of carnosine.
CPC Classifications
A61K 38/05 A61K 9/0043 A61K 9/1075 A61K 47/12 A61K 47/183 A61K 47/26 A61K 47/38 A61K 47/40 A61P 25/16
Filing Date
2025-03-04
Application No.
19070338
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.